Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase

Nenhuma Miniatura disponível




Rodrigues, Mariane A.D.
Pimenta, Marcela V.
Costa, Iris M.
Zenatti, Priscila P.
Migita, Natacha A.
Yunes, José A.
Rangel-Yagui, Carlota O.
de Sá, Matheus M.
Pessoa, Adalberto
Costa-Silva, Tales A.

Título da Revista

ISSN da Revista

Título de Volume



L-asparaginase (ASNase) from Escherichia coli (EcAII) is used in the treatment of acute lymphoblastic leukaemia (ALL). EcAII activity in vivo has been described to be influenced by the human lysosomal proteases asparaginyl endopeptidase (AEP) and cathepsin B (CTSB); these hydrolases cleave and could expose epitopes associated with the immune response against EcAII. In this work, we show that ASNase resistance to CTSB and/or AEP influences the formation of anti-ASNase antibodies, one of the main causes of hypersensitivity reactions in patients. Error-prone polymerase chain reaction was used to produce variants of EcAII more resistant to proteolytic cleavage by AEP and CTSB. The variants with enzymatic activity and cytotoxicity levels equivalent to or better than EcAII WT were submitted to in vivo assays. Only one of the mutants presented increased serum half-life, so resistance to these proteases is not the only feature involved in EcAII stability in vivo. Our results showed alteration of the phenotypic profile of B cells isolated after animal treatment with different protease-resistant proteoforms. Furthermore, mice that were exposed to the protease-resistant proteoforms presented lower anti-asparaginase antibodies production in vivo. Our data suggest that modulating resistance to lysosomal proteases can result in less immunogenic protein drugs.



Acute lymphoblastic leukaemia, Biopharmaceutical, Error-prone polymerase chain reaction, Human proteases, L-asparaginase, Protein stability

Como citar

Biochemical Pharmacology, v. 182.